CN107937324B - Lactobacillus crispatus and application thereof - Google Patents
Lactobacillus crispatus and application thereof Download PDFInfo
- Publication number
- CN107937324B CN107937324B CN201810022714.0A CN201810022714A CN107937324B CN 107937324 B CN107937324 B CN 107937324B CN 201810022714 A CN201810022714 A CN 201810022714A CN 107937324 B CN107937324 B CN 107937324B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus crispatus
- fermentation broth
- strain
- lactobacillus
- crispatus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/56—Lactic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses lactobacillus crispatus and application thereof. The Lactobacillus crispatus provided by the invention is specifically Lactobacillus crispatus (L49), and the preservation number of the Lactobacillus crispatus in the China general microbiological culture Collection center is CGMCC No. 15154. Experiments prove that Lactobacillus crispatus L49 has an antibacterial effect, has good inhibitory activity on pathogenic fungi Candida albicans, can be used for adjusting the microecological balance of female genital tracts, preventing diseases of female genital tracts and reducing the probability of the diseases of female genital tracts, and has very important significance on female reproductive health, prenatal and postnatal care of population and harmonious and stable family and society.
Description
Technical Field
The invention relates to the field of microorganisms, and particularly relates to lactobacillus crispatus and application thereof.
Background
Female genital infections have become one of the most important infectious diseases that are serious global hazards, and millions of women suffer from the disease every year worldwide. Among them, bacterial genital tract diseases (BV) and vulvogenital tract candidiasis (VVC) are the most common infections, the incidence rate is about 75%, and the treatment is troublesome and easy to recur, has large harm to physical and mental health of patients, seriously affects daily work or life, or causes serious complications such as sterility, premature birth, cervical cancer, HIV infection and the like. In addition, with the emergence of antibiotic resistant strains, it is increasingly difficult to treat genital tract infectious diseases, and the development of improved drugs and new therapeutic approaches is of great importance. Therefore, the use of probiotic micro-ecological agents, such as live lactobacillus preparations, for restoring the dominance of lactobacillus in the genital tract and for preventing and treating diseases such as genital tract infection has become a potential application direction.
Lactobacillus crispatus is a dominant lactobacillus in the reproductive tract of healthy women, and plays a key role in maintaining the flora balance and health of the reproductive tract. It can inhibit various pathogenic bacteria and fungi of genital tract, such as Gardnerella and Candida albicans, and reduce the risk of HIV infection and sexually transmitted diseases, and is an ideal probiotic for genital tract. Understanding some probiotic properties of lactobacillus crispatus, such as acid production capacity, adhesion capacity, ability to ferment carbohydrates and ability to inhibit pathogenic fungi of the reproductive tract, and applying it to the treatment and prevention of reproductive tract diseases, is of great importance to female reproductive health, better growth and well-being of the population and the harmony and stability of the family and society.
Disclosure of Invention
The invention aims to provide lactobacillus crispatus derived from healthy female genital tracts and application thereof.
The Lactobacillus crispatus provided by the invention is L49, the strain has been preserved in China general microbiological culture Collection center (CGMCC for short, address: Beijing city Shanghai Chen Xilu No.1 Hospital No. 3) in 03.01.2018, and the preservation number is CGMCC No. 15154.
The invention also provides a microbial inoculum.
The active ingredient of the microbial inoculum provided by the invention is the Lactobacillus crispatus L49.
The fermentation liquor or the filtrate of the fermentation liquor of the Lactobacillus crispatus L49 also belongs to the protection scope of the invention.
In one embodiment of the present invention, the fermentation broth is specifically a fermentation broth obtained by inoculating the lactobacillus crispatus L49 in an MRS medium and performing stationary culture at 37 ℃. Among them, the culture time is preferably 15 hours or more.
The metabolite of the Lactobacillus crispatus L49 also belongs to the protection scope of the invention.
A bacterial suspension of the Lactobacillus crispatus L49 also belongs to the protection scope of the invention.
A culture solution for culturing the L49 strain of Lactobacillus crispatus (Lactobacillus crispatus) also belongs to the protection scope of the invention.
The application of the Lactobacillus crispatus L49 or the microbial inoculum or the fermentation liquor or the filtrate or metabolite of the fermentation liquor or the bacterial suspension or the culture solution in any one of the following methods also belongs to the protection scope of the invention:
(a1) antibacterial and/or bacteriostatic;
(a2) preparing the product with the antibacterial and/or bacteriostatic functions.
Wherein, the antibiosis refers to a process of sterilizing or hindering the growth and the reproduction of bacteria and the activity thereof by adopting a chemical or physical method; including sterilization and bacteriostasis. The bacteriostasis refers to a process of inhibiting bacteria or hindering the growth and the reproduction of the bacteria and the activity thereof by adopting a chemical or physical method.
In the present invention, the bacterium is a fungus.
More specifically, the fungus is candida albicans.
In one embodiment of the invention, the inhibition of the growth of candida albicans and/or the formation of candida albicans hyphae is embodied.
The application of the Lactobacillus crispatus L49 or the microbial inoculum or the fermentation liquor or the filtrate or metabolite of the fermentation liquor or the bacterial suspension or the culture solution in any one of the following methods also belongs to the protection scope of the invention:
(b1) regulating microecological balance of female genital tract;
(b2) preparing the product for regulating the microecological balance of female genital tract.
The application of the Lactobacillus crispatus L49 or the microbial inoculum or the fermentation liquor or the filtrate or metabolite of the fermentation liquor or the bacterial suspension or the culture solution in any one of the following methods also belongs to the protection scope of the invention:
(c1) preventing and/or treating infections and/or sexually transmitted diseases of the female genital tract;
(c2) preparing products for preventing and/or treating female genital tract infection and/or sexually transmitted diseases.
The application of the Lactobacillus crispatus L49 or the microbial inoculum in any one of the following methods also belongs to the protection scope of the invention:
(d1) producing lactic acid;
(d2) preparing a product for producing lactic acid.
Wherein the lactic acid is mainly D-type lactic acid.
The application of the Lactobacillus crispatus L49 or the microbial inoculum in any one of the following methods also belongs to the protection scope of the invention:
(e1) adherent cervical cancer cells;
(e2) preparing a product for adhering cervical cancer cells.
In one embodiment of the invention, the cervical cancer cells are specifically Hela cells.
The invention provides a strain of Lactobacillus crispatus L49. Experiments prove that Lactobacillus crispatus L49 has an antibacterial effect, has good inhibitory activity on pathogenic fungi Candida albicans, can be used for adjusting the microecological balance of female genital tracts, preventing diseases of female genital tracts and reducing the probability of the diseases of female genital tracts, and has very important significance on female reproductive health, prenatal and postnatal care of population and harmonious and stable family and society.
Deposit description
The strain name is as follows: lactobacillus crispatus
Latin name: lactobacillus crispatus
The strain number is as follows: l49
The preservation organization: china general microbiological culture Collection center
The preservation organization is abbreviated as: CGMCC (China general microbiological culture Collection center)
Address: xilu No.1 Hospital No. 3 of Beijing market facing Yang district
The preservation date is as follows: 03 month of 2018
Registration number of the preservation center: CGMCC No.15154
Drawings
FIG. 1 shows the analysis result of lactic acid content in L49 strain fermentation liquid. The strain A is L49, the lactic acid is produced more quickly, and the acid production reaches the maximum of about 150mM after fermentation for about 15 hours; b is L49 strain producing more D-lactic acid, and the D-lactic acid yield in stationary phase is about 110mM/108cfu。
FIG. 2 shows the results of analysis of adhesion of cervical cancer cell Hela by L49 strain.
FIG. 3 shows the results of experiments on the growth inhibition of Candida albicans by L49 strain.
FIG. 4 shows the results of experiments on the inhibition of Candida albicans hyphae formation by the L49 strain. The "control" in the figure is fresh MRS medium.
FIG. 5 shows the results of analysis of the ability of L49 strain to utilize carbohydrates.
Detailed Description
The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Candida albicans SC5314(Candida albicans SC5314) in the following examples is disclosed in the documents "Xie J, TaoL, Nobile CJ, Tong Y, Guan G, Sun Y, Cao C, Hernday AD, Johnson AD, Zhang L, Bai FY, Huang G (2013), White-opaque switching in natural MTLa/α isolates of Candida albicans: evolution activities for rollers in host adaptation, pathobiology, and sex. PLoS Biol 11(3): e1521005", publicly available from the institute of microbiology in the national academy of sciences, and can be used only in the heavy inventions.
Example 1 isolation and identification of L49 Strain
Isolation of the first, L49 Strain
L49 was isolated from the reproductive tract of healthy women. The specific separation method is as follows: the genital tract swab was placed in a sterile PBS tube containing 1mL for 30s with shakingTen times dilution of stock solution, spreading 100 μ L of 10000 times diluted liquid on MRS culture medium solid plate (1L of MRS culture medium formula is beef extract 10g, casein peptone 10g, yeast extract 5g, glucose 20g, sodium acetate 5g, diammonium citrate 2g, Tween 801 mL, K2HPO42g，MgSO4.7H2O 0.58g，MnSO4.H2O0.25g, 15g of agar powder, double distilled water to l L, autoclaving), and culturing at 37 deg.C for 48h in an anaerobic incubator. Then, single clones were picked and cultured in MRS liquid medium. After overnight culture, the bacteriostatic activity of the monoclone fermentation broth supernatant on candida albicans SC5314 is detected, and the bacteriostatic activity of one strain is found to be very strong, which is named as L49.
II, identification of L49 Strain
L49 cells were cultured and collected, genomic DNA was extracted, and the 16S rRNA sequence was amplified using primers (27F: 5'-AGAGTTTGATCCTGGCTCAG-3' and 1492R: 5'-GGTTACCTTGTTACGACTT-3') to obtain a PCR product. And sequencing the PCR product.
The sequencing result shows that: the sequence of the PCR product is shown in SEQ ID No.1, and the sequence is identified as Lactobacillus crispatus by comparison analysis on NCBI website (https:// blast.ncbi.nlm.nih.gov/blast.cgi).
According to the identification result, the L49 strain is named as Lactobacillus crispatus, which is classified and named as Lactobacillus crispatus, and is preserved in China general microbiological culture Collection center (CGMCC for short, the address: No. 3 Xilu 1 of Beijing university at sunward north Cheng, the institute of microbiology, China academy of sciences, postal code 100101) in 03.2018.01.03.A preservation number is CGMCC No. 15154.
Example 2 analysis of lactic acid content in supernatant of fermentation broth of L49 Strain
Lactic Acid (LA) is an important probiotic substance, and the content of D-type lactic acid in the genital tract environment is in positive correlation with genital tract health, which is an important standard for evaluating the properties of genital tract probiotics.
The L49 strain isolated in example 1 was inoculated into MRS medium and incubated at 37 ℃ in a static mannerCulturing to obtain L49 fermentation liquid (setting different culture time). The L49 fermentation liquid is centrifuged for 5min under the condition of 12000g, and the supernatant of the L49 fermentation liquid is collected. The supernatant of the L49 fermentation liquid is filtered by a 0.2 μm filter, diluted 5 times by deionized water, and then the lactic acid content in the supernatant is determined by adopting an organic acid analytical column combined with high performance liquid chromatography. And simultaneously diluting the supernatant by 50 times with deionized water, and analyzing the content of L-type (L-LA) and D-type (D-LA) lactic acid in the supernatant by using a chiral column combined with high performance liquid chromatography. Wherein, the chiral column is MCI GEL CRS10W, and the chromatographic conditions are as follows: the mobile phase is 2mM GuSO4The flow rate was 0.5mL/min, and the detection wavelength was 254 nm.
The results show that: (1) the L49 strain produced more lactic acid faster, and the acid production reached a maximum of about 150mM around 15 hours of fermentation (A in FIG. 1). (2) The L49 strain produces more D-type lactic acid, and the yield of the D-type lactic acid in the stationary phase is about 110mM/108cfu (B in FIG. 1).
Example 3 probiotic characterisation of the L49 Strain
First, analysis of adhesion of L49 strain to cervical cancer cell Hela
HeLa cells are derived from cervical cancer cells in women, proliferate rapidly, and are commonly used as replacement cells for vaginal epithelial cells for in vitro studies. The stronger the adhesion of the probiotics to epithelial cells, the more beneficial the probiotics to colonize human bodies, compete with pathogenic bacteria for occupation, prevent the invasion of the pathogenic bacteria and more beneficial the probiotics function.
Culturing HeLa cells with 1640 cell culture medium at 37 deg.C containing 5% CO2An incubator. When the Hela cells on the cover glass of the cell culture plate grow to be full of 80 percent, the cell culture plate is cultured for 24 hours by 1640 cell culture solution without penicillin and streptomycin. Before the adhesion experiment, cells were washed three times with PBS. The L49 cells were resuspended in PBS phosphate buffer and washed three times with phosphate buffer. In the adhesion experiment, 1mL of 1640 cell culture solution containing no penicillin, streptomycin and calf serum was added to each well of the cell culture plate, and mixed with 1mL of L49 cell suspension. Culturing the cell culture plate in incubator for 2.5 hr, taking out the cover glass, washing with cold PBS for three times, naturally drying at room temperature (25 deg.C), fixing with methanol, gram staining, and oil lensAdhesion of the L49 strain to Hela cells was observed.
The results show that: the L49 strain adhered strongly to Hela cells, with more bacteria adhering to the periphery of each cell (FIG. 2).
II, inhibition of Candida albicans growth by L49 strain
Candida albicans is a common pathogenic bacterium causing genital tract infection, and the candidiasis caused by the Candida albicans is difficult to treat, is easy to cause mixed infection with other pathogenic microorganisms, and poses serious threat to life. In addition, the recent emergence of drug-resistant candida albicans has made its treatment more intractable, and thus probiotic preparations with inhibitory effects are an effective means for the prevention and treatment of the disease.
L49 strain and Candida albicans SC5314 were cultured in MRS medium and YPD medium (1L YPD medium formulation: yeast extract 10g, peptone 20g, and glucose 20g, autoclaved) at 37 ℃ respectively. The respective cells were collected and washed 2 times with MRS medium, and then L49 and SC5314 were expressed at 1X 108cfu/mL and 1X 107cfu/mL was added to MRS medium for co-culture, and samples were diluted at different time points in MRS (containing 50. mu.g/mL natamycin) and YPD (containing 100. mu.g/mL ampicillin) media for counting viable cell counts of L49 and SC5314, respectively.
The results show that: the L49 strain has obvious effect of inhibiting the candida albicans, the growth of the candida albicans is obviously slowed down at the beginning of co-culture, the number of the candida albicans starts to be sharply reduced at about 12h, and the mortality rate of the candida albicans reaches 99% at 22h (figure 3).
Inhibition of L49 strain on Candida albicans hyphae
When candida albicans is pathogenic, the yeast phase is in morphological transformation to the mycelium phase, so that a dense biofilm can be formed to cause serious tissue infection, and if the morphological transformation can be inhibited, the toxicity of the candida albicans is greatly reduced.
Candida albicans SC5314 was cultured overnight in YPD medium, collected, washed 2 times with PBS buffer, and resuspended in 100% fetal bovine serum. Then, 100. mu.L of the resuspended solution and 100. mu.L of the supernatant of the fermentation broth L49 were mixed and added to a 96-well plate, and the plate was left in an incubator at 37 ℃ for 2 hours. The amount of hyphae formed in the 96-well plates by SC5314 was quantitatively analyzed by crystal violet staining. The specific operation is as follows: first, the non-adsorbed cells were aspirated and washed with 70% ethanol, 0.25% SDS and sterile water in this order. After staining for 5 minutes by adding 0.1% crystal violet, the cells were washed with sterile water and SDS. Finally, the adsorbed cells were resuspended in 0.04M HCl-isopropanol solution and 0.25% SDS, and the absorbance at 590nm wavelength in each well was measured using a spectrophotometer.
The results show that: the supernatant of the L49 strain fermentation liquor has obvious inhibition effect on the formation of candida albicans hyphae, and the inhibition rate reaches about 90 percent (figure 4).
Analysis of carbohydrate utilization ability of Strain IV, L49
The utilization of the probiotics to carbohydrates, particularly oligosaccharides and/or polysaccharides in the physiological environment can increase the colonization ability of the probiotics in the physiological environment, and is more beneficial to the probiotics effect to be exerted for a long time.
The L49 strain was analyzed for growth in media containing different carbohydrates. These carbohydrates include maltotriose, soluble starch, pullulan and amylopectin. These carbohydrates were added to MRS medium containing no glucose at a final concentration of 0.5% (mass concentration), and after standing culture at 37 ℃ for 24 hours, the OD of L49 under each carbohydrate was measured with a spectrophotometer600The value is obtained.
The results show that: the L49 strain grew well in the above carbohydrate medium, indicating that it has a strong ability to utilize both oligosaccharides and polysaccharides (FIG. 5).
<110> institute of microbiology of Chinese academy of sciences
<120> lactobacillus crispatus strain and application thereof
<130>GNCLN180022
<160>1
<170>PatentIn version 3.5
<210>1
<211>1405
<212>DNA
<213> Lactobacillus crispatus (Lactobacillus crispatus)
<400>1
cgagcggaac taacagattt acttcggtaa tgacgttagg aaagcgagcg gcggatgggt 60
gagtaacacg tgggaaacct gccccatagt ctgggatacc acttggaaac aggtgctaat 120
accggataag aaagcagatc gcatgatcag cttttaaaag gcggcgtaag ctgtcgctat 180
gggatggccc cgcggtgcat tagctagttg gtaaggtaaa ggcttaccaa ggcgatgatg 240
catagccgag ttgagagact gatcggccac attgggactg agacacggcc caaactccta 300
cgggaggcag cagtagggaa tcttccacaa tggacgcaag tctgatggag caacgccgcg 360
tgagtgaaga aggttttcgg atcgtaaagc tctgttgttg gtgaagaagg atagaggtag 420
taactggcct ttatttgacg gtaatcaacc agaaagtcac ggctaactac gtgccagcag 480
ccgcggtaat acgtaggtgg caagcgttgt ccggatttat tgggcgtaaa gcgagcgcag 540
gcggaagaat aagtctgatg tgaaagccct cggcttaacc gaggaactgc atcggaaact 600
gtttttcttg agtgcagaag aggagagtgg aactccatgt gtagcggtgg aatgcgtaga 660
tatatggaag aacaccagtg gcgaaggcgg ctctctggtc tgcaactgac gctgaggctc 720
gaaagcatgg gtagcgaaca ggattagata ccctggtagt ccatgccgta aacgatgagt 780
gctaagtgtt gggaggtttc cgcctctcag tgctgcagct aacgcattaa gcactccgcc 840
tggggagtac gaccgcaagg ttgaaactca aaggaattga cgggggcccg cacaagcggt 900
ggagcatgtg gtttaattcg aagcaacgcg aagaacctta ccaggtcttg acatctagtg 960
ccatttgtag agatacaaag ttcccttcgg ggacgctaag acaggtggtg catggctgtc 1020
gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac gagcgcaacc cttgttatta 1080
gttgccagca ttaagttggg cactctaatg agactgccgg tgacaaaccg gaggaaggtg 1140
gggatgacgt caagtcatca tgccccttat gacctgggct acacacgtgc tacaatgggc 1200
agtacaacga gaagcgagcc tgcgaaggca agcggatctc tgaaagctgt tctcagttcg 1260
gactgcagtc tgcaactcga ctgcacgaag ctggaatcgc tagtaatcgc ggatcagcac 1320
gccgcggtga atacgttccc gggccttgta cacaccgccc gtcacaccat gggagtctgc 1380
aatgcccaaa gccggtggcc taacc 1405
Claims (10)
1. Lactobacillus crispatus: (Lactobacillus crispatus) L49 with the preservation number of CGMCC No.15154 in China general microbiological culture Collection center.
2. A microbial agent comprising the Lactobacillus crispatus strain of claim 1 as an active ingredientLactobacillus crispatus）L49。
3. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) The fermentation broth of L49 or a filtrate of the fermentation broth.
4. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) L49.
5. Cultured with the Lactobacillus crispatus strain of claim 1 (L.), (Lactobacillus crispatus) L49.
6. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) Use of L49 or the microbial inoculum of claim 2 or the fermentation broth or filtrate of the fermentation broth of claim 3 or the bacterial suspension of claim 4 or the culture broth of claim 5 for the preparation of a product with anti-Candida albicans and/or Candida albicans inhibiting function.
7. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) Use of L49 or the bacterial agent of claim 2 or the fermentation broth or filtrate of the fermentation broth of claim 3 or the bacterial suspension of claim 4 or the culture broth of claim 5 for the preparation of a product for regulating the microecological balance of the female genital tract.
8. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) Use of L49 or the bacterial agent of claim 2 or the fermentation broth or filtrate of the fermentation broth of claim 3 or the bacterial suspension of claim 4 or the culture solution of claim 5 for the preparation of a product for the prevention and/or treatment of infections of the genital tract and/or sexually transmitted diseases in women.
9. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) Use of L49 or the bacterial agent of claim 2 in any one of:
(d1) producing lactic acid;
(d2) preparing a product for producing lactic acid.
10. Lactobacillus crispatus (L) as claimed in claim 1Lactobacillus crispatus) Use of L49 or the bacterial agent of claim 2 in the preparation of a product for adhering cervical cancer cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810022714.0A CN107937324B (en) | 2018-01-10 | 2018-01-10 | Lactobacillus crispatus and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810022714.0A CN107937324B (en) | 2018-01-10 | 2018-01-10 | Lactobacillus crispatus and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107937324A CN107937324A (en) | 2018-04-20 |
| CN107937324B true CN107937324B (en) | 2020-01-21 |
Family
ID=61937601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810022714.0A Active CN107937324B (en) | 2018-01-10 | 2018-01-10 | Lactobacillus crispatus and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107937324B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110982726B (en) * | 2019-08-09 | 2020-07-24 | 四川厌氧生物科技有限责任公司 | Lactobacillus crispatus and application thereof |
| CN112899182B (en) * | 2021-01-08 | 2023-03-24 | 安徽省肿瘤医院 | Lactobacillus crispatus capable of preventing and/or treating cervical squamous cell carcinoma |
| CN115404185A (en) * | 2022-08-31 | 2022-11-29 | 江苏新申奥生物科技有限公司 | Lactobacillus crispatus LCP051 for antagonizing candida albicans and application thereof |
| CN115851504A (en) * | 2022-09-30 | 2023-03-28 | 广东君薇生物科技有限公司 | Probiotics, composition and application thereof |
| CN116286484A (en) * | 2023-02-08 | 2023-06-23 | 南昌大学 | Lactobacillus crispatus and uses thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1894996A1 (en) * | 1998-04-10 | 2008-03-05 | Proge Farm S.r.l. | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures |
| CN103074270A (en) * | 2012-11-15 | 2013-05-01 | 上海交大昂立股份有限公司 | Lactobacillus crispatus and application |
| CN103911307A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and its uses |
| CN103911305A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and uses thereof |
| CN104178437A (en) * | 2013-11-08 | 2014-12-03 | 苏州欧赛微科生物医药科技有限公司 | Lactobacillus crispatus and its application in gynecological diseases |
| CN104232537A (en) * | 2014-09-03 | 2014-12-24 | 中国科学院微生物研究所 | Lactobacillus crispatus and application thereof |
| CN104508117A (en) * | 2012-07-09 | 2015-04-08 | S.P.M.D公司 | Novel strain of lactobacillus crispatus |
| CN104630083A (en) * | 2013-11-08 | 2015-05-20 | 苏州欧赛微科生物医药科技有限公司 | Lactobacillus crispatus and applications thereof in woman healthcare products |
| CN105349474A (en) * | 2015-12-17 | 2016-02-24 | 中国科学院微生物研究所 | Lactobacillus.crispatus for preventing female urogenital tract infection |
| WO2017148975A1 (en) * | 2016-03-01 | 2017-09-08 | Biose | Compositions for treating candidiasis infections |
| CN107794236A (en) * | 2017-10-10 | 2018-03-13 | 内蒙古双奇药业股份有限公司 | A kind of Lactobacillus crispatus and its application |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104293718B (en) * | 2014-10-11 | 2017-01-18 | 中国科学院微生物研究所 | Lactobacillus jensenii and application thereof |
| CN105400724A (en) * | 2015-12-17 | 2016-03-16 | 中国科学院微生物研究所 | Lactobacillus. crispatus strain, and microecological preparation thereof |
-
2018
- 2018-01-10 CN CN201810022714.0A patent/CN107937324B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1894996A1 (en) * | 1998-04-10 | 2008-03-05 | Proge Farm S.r.l. | Lactobacilli strains having inhibitory and/or microbicidal activity against pathogenic microorganisms and a method for inducing and keeping said activity in lactobacilli cultures |
| CN104508117A (en) * | 2012-07-09 | 2015-04-08 | S.P.M.D公司 | Novel strain of lactobacillus crispatus |
| CN103074270A (en) * | 2012-11-15 | 2013-05-01 | 上海交大昂立股份有限公司 | Lactobacillus crispatus and application |
| CN103911307A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and its uses |
| CN103911305A (en) * | 2013-01-05 | 2014-07-09 | 欣力菲生物医药技术（天津）有限公司 | Lactobacillus crispatus strain and uses thereof |
| CN104178437A (en) * | 2013-11-08 | 2014-12-03 | 苏州欧赛微科生物医药科技有限公司 | Lactobacillus crispatus and its application in gynecological diseases |
| CN104630083A (en) * | 2013-11-08 | 2015-05-20 | 苏州欧赛微科生物医药科技有限公司 | Lactobacillus crispatus and applications thereof in woman healthcare products |
| CN104232537A (en) * | 2014-09-03 | 2014-12-24 | 中国科学院微生物研究所 | Lactobacillus crispatus and application thereof |
| CN105349474A (en) * | 2015-12-17 | 2016-02-24 | 中国科学院微生物研究所 | Lactobacillus.crispatus for preventing female urogenital tract infection |
| WO2017148975A1 (en) * | 2016-03-01 | 2017-09-08 | Biose | Compositions for treating candidiasis infections |
| CN107794236A (en) * | 2017-10-10 | 2018-03-13 | 内蒙古双奇药业股份有限公司 | A kind of Lactobacillus crispatus and its application |
Non-Patent Citations (1)
| Title |
|---|
| 人源性乳酸杆菌的生物学特征研究与优选;曾朱君等;《国际检验医学杂志》;20151231;第36卷(第12期);第1771-1773页，参见全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107937324A (en) | 2018-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107937324B (en) | Lactobacillus crispatus and application thereof | |
| CN107299065B (en) | Lactobacillus plantarum and application thereof in preparation of vagina bacteriostatic drugs | |
| CN1888051B (en) | Plant lactobacillus strain and its application | |
| JP2022524157A (en) | Composite Lactobacillus Composition and Its Uses in Vaginal Health in Women | |
| TW201531560A (en) | Lactobacillus crispatus and application thereof | |
| KR20180006998A (en) | Lactobacilli having inhibitory effect against pathogenic microorganisms in vagina | |
| KR101720145B1 (en) | Cosmetic composition for prevention and improvement of vaginosis | |
| DK2555785T3 (en) | Use of Streptococcus salivarius in the treatment of chronic respiratory tract infections | |
| CN116200306B (en) | Lactobacillus rhamnosus LRa16, and application and product thereof in preparation of medicines for treating genital tract infection | |
| CN111518714B (en) | Lactobacillus crispatus capable of preventing and/or treating candida vaginitis | |
| CN110777087A (en) | Lactobacillus johnsonii and application thereof | |
| CN115851500B (en) | Lactobacillus plantarum and application thereof | |
| CN113862188A (en) | Lactobacillus gasseri LS03 and application thereof | |
| CN114561330B (en) | Composite microbial inoculum for preventing and treating genital tract infection | |
| CN103409334A (en) | Lactobacillus for inhibiting pathogenic bacteria of vaginitis and application thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN110540945A (en) | lactobacillus jensenii and application thereof in preparation of vaginal antibacterial drugs | |
| CN104232537B (en) | Lactobacillus crispatus and application thereof | |
| CN112806576A (en) | Composition for inhibiting pathogenic bacteria of vaginitis, vagina cleaning composition and application thereof | |
| CN111419829B (en) | Application of honokiol in inhibiting streptococcus suis or biofilm thereof | |
| CN111567807A (en) | Rhamnose-containing lactobacillus composition for inhibiting inflammatory reaction and resisting vaginitis and application thereof | |
| CN115074286B (en) | Bacillus pumilus for antagonizing tinea pedis pathogenic fungi and application thereof | |
| CN108795809B (en) | Product and the application of a kind of lactobacillus plantarum JYLP-002 and its preparation | |
| CN115850409B (en) | Leader-free bacteriocin A3 resistant to multiple pathogenic bacteria, and preparation method and application thereof | |
| CN111778178A (en) | Application of marine streptomyces griseoflavus HN60 in antibacterial aspect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |